Abstract

Sickle cell disease (SCD) leads to significant morbidity and early mortality, and hematopoietic cell transplantation (HCT) is the only widely available cure, with impacts seen on SCD-related organ dysfunction. Outcomes are excellent following matched-related donor (MRD) HCT, leading to significantly expanded application of this treatment over the past decade. The majority of SCD patients lack an MRD, but outcomes following alternative donor HCT continue to improve on clinical trials. Within this framework, we aim to provide our perspective on how to apply research findings to clinical practice, for an individual patient. We also emphasize that the preparation of SCD recipients for HCT and supporting them through HCT have special nuances that require awareness and close attention. Through the use of clinical vignettes, we provide our perpsective on the complex decision-making process in HCT for SCD as well as recommendations for the evaluation and support of these patients through HCT.

REFERENCES

REFERENCES
1.
Walters
MC
,
Patience
M
,
Leisenring
W
, et al
.
Bone marrow transplantation for sickle cell disease
.
N Engl J Med
.
1996
;
335
(
6
):
369
-
376
.
2.
King
AA
,
Kamani
N
,
Bunin
N
, et al
.
Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies
.
Am J Hematol
.
2015
;
90
(
12
):
1093
-
1098
.
3.
Bernaudin
F
,
Socie
G
,
Kuentz
M
, et al;
SFGM-TC
.
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
.
Blood
.
2007
;
110
(
7
):
2749
-
2756
.
4.
Gluckman
E
,
Cappelli
B
,
Bernaudin
F
, et al;
Eurocord, the Pediatric Working Party of the European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research
.
Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation
.
Blood
.
2017
;
129
(
11
):
1548
-
1556
.
5.
Krishnamurti
L
,
Neuberg
DS
,
Sullivan
KM
, et al
.
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study
.
Am J Hematol
.
2019
;
94
(
4
):
446
-
454
.
6.
Shenoy
S
,
Eapen
M
,
Panepinto
JA
, et al
.
A trial of unrelated donor marrow transplantation for children with severe sickle cell disease
.
Blood
.
2016
;
128
(
21
):
2561
-
2567
.
7.
Abraham
A
,
Cluster
A
,
Jacobsohn
D
, et al
.
Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial
.
Biol Blood Marrow Transplan
.
2017
;
23
:
1587
-
1592
.
8.
Bolaños-Meade
J
,
Fuchs
EJ
,
Luznik
L
, et al
.
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease
.
Blood
.
2012
;
120
(
22
):
4285
-
4291
.
9.
Saraf
SL
,
Oh
AL
,
Patel
PR
, et al
.
Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease
.
Biol Blood Marrow Transplant
.
2018
;
24
:
1759
-
1765
.
10.
Hsieh
MM
,
Fitzhugh
CD
,
Weitzel
RP
, et al
.
Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype
.
JAMA
.
2014
;
312
(
1
):
48
-
56
.
11.
Fitzhugh
CD
,
Hsieh
MM
,
Taylor
T
, et al
.
Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT
.
Blood Adv
.
2017
;
1
(
11
):
652
-
661
.
12.
Guilcher
GMT
,
Monagel
DA
,
Nettel-Aguirre
A
, et al
.
Nonmyeloablative matched sibling donor hematopoietic cell transplantation in children and adolescents with sickle cell disease
.
Biol Blood Marrow Transplant
.
2019
;
25
(
6
):
1179
-
1186
.
13.
de la Fuente
J
,
Dhedin
N
,
Koyama
T
, et al
.
Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative
.
Biol Blood Marrow Transplant
.
2019
;
25
:
1197
-
1209
.
14.
Hassell
KL
.
Population estimates of sickle cell disease in the U.S
.
Am J Prev Med
.
2010
;
38
(
suppl 4
):
S512
-
S521
.
15.
Johnson
FL
,
Look
AT
,
Gockerman
J
,
Ruggiero
MR
,
Dalla-Pozza
L
,
Billings
FT
III
.
Bone-marrow transplantation in a patient with sickle-cell anemia
.
N Engl J Med
.
1984
;
311
(
12
):
780
-
783
.
16.
Walters
MC
,
Storb
R
,
Patience
M
, et al
.
Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease
.
Blood
.
2000
;
95
(
6
):
1918
-
1924
.
17.
Walters
MC
,
Patience
M
,
Leisenring
W
, et al
.
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia
.
Biol Blood Marrow Transplant
.
2001
;
7
:
665
-
673
.
18.
Locatelli
F
,
Kabbara
N
,
Ruggeri
A
, et al;
Eurocord and European Blood and Marrow Transplantation (EBMT) group
.
Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling
.
Blood
.
2013
;
122
(
6
):
1072
-
1078
.
19.
Krishnamurti
L
,
Kharbanda
S
,
Biernacki
MA
, et al
.
Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease
.
Biol Blood Marrow Transplant
.
2008
;
14
:
1270
-
1278
.
20.
Ozdogu
H
,
Boga
C
,
Yeral
M
, et al
.
Allogenic peripheral stem cell transplantation from HLA-matched related donors for adult sickle cell disease: remarkable outcomes from a single-center trial
.
Bone Marrow Transplant
.
2018
;
53
(
7
):
880
-
890
.
21.
Saraf
SL
,
Oh
AL
,
Patel
PR
, et al
.
Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease
.
Biol Blood Marrow Transplant
.
2016
;
22
:
441
-
448
.
22.
Bernaudin
F
,
Verlhac
S
,
Peffault de Latour
R
, et al;
DREPAGREFFE Trial Investigators
.
Association of matched sibling donor hematopoietic stem cell transplantation with transcranial Doppler velocities in children with sickle cell anemia
.
JAMA
.
2019
;
321
(
3
):
266
-
276
.
23.
Nickel
RS
,
Seashore
E
,
Lane
PA
, et al
.
Improved splenic function after hematopoietic stem cell transplant for sickle cell disease
.
Pediatr Blood Cancer
.
2016
;
63
(
5
):
908
-
913
.
24.
Walters
MC
,
Hardy
K
,
Edwards
S
, et al
.
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease
.
Biol Blood Marrow Transplant
.
2010
;
16
:
263
-
272
.
25.
King
AA
,
McKinstry
RC
,
Wu
J
, et al
.
Functional and radiologic assessment of the brain after reduced-intensity unrelated donor transplantation for severe sickle cell disease–Blood and Marrow Transplant Clinical Trials Network #0601
.
Biol Blood Marrow Transplant
.
2019
;
25
(
5
):
e174
-
e178
.
26.
Bhatia
M
,
Kolva
E
,
Cimini
L
, et al
.
Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease
.
Biol Blood Marrow Transplant
.
2015
;
21
:
666
-
672
.
27.
Dallas
MH
,
Triplett
B
,
Shook
DR
, et al
.
Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease
.
Biol Blood Marrow Transplant
.
2013
;
19
:
820
-
830
.
28.
Guilcher
GMT
,
Truong
TH
,
Saraf
SL
,
Joseph
JJ
,
Rondelli
D
,
Hsieh
MM
.
Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease
.
Semin Hematol
.
2018
;
55
(
2
):
87
-
93
.
29.
Joseph
JJ
,
Abraham
AA
,
Fitzhugh
CD
.
When there is no match, the game is not over: Alternative donor options for hematopoietic stem cell transplantation in sickle cell disease
.
Semin Hematol
.
2018
;
55
(
2
):
94
-
101
.
30.
Walters
MC
,
Patience
M
,
Leisenring
W
, et al
.
Barriers to bone marrow transplantation for sickle cell anemia
.
Biol Blood Marrow Transplant
.
1996
;
2
:
100
-
104
.
31.
Gragert
L
,
Eapen
M
,
Williams
E
, et al
.
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry
.
N Engl J Med
.
2014
;
371
(
4
):
339
-
348
.
32.
Justus
D
,
Perez-Albuerne
E
,
Dioguardi
J
,
Jacobsohn
D
,
Abraham
A
.
Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease
.
Pediatr Blood Cancer
.
2015
;
62
(
7
):
1285
-
1287
.
33.
Kamani
NR
,
Walters
MC
,
Carter
S
, et al
.
Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
.
Biol Blood Marrow Transplant
.
2012
;
18
:
1265
-
1272
.
34.
Ruggeri
A
,
Eapen
M
,
Scaravadou
A
, et al
.
Umbilical cord blood transplantation for children with thalassemia and sickle cell disease
.
Biol Blood Marrow Transplant
.
2011
;
17
:
1375
-
1382
.
35.
Wagner
JE
Jr.
,
Brunstein
CG
,
Boitano
AE
, et al
.
Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft
.
Cell Stem Cell
.
2016
;
18
(
1
):
144
-
155
.
36.
Pawlowska
AB
,
Cheng
JC
,
Karras
NA
, et al
.
HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease
.
Biol Blood Marrow Transplant
.
2018
;
24
:
185
-
189
.
37.
Smith
WR
,
Penberthy
LT
,
Bovbjerg
VE
, et al
.
Daily assessment of pain in adults with sickle cell disease
.
Ann Intern Med
.
2008
;
148
(
2
):
94
-
101
.
38.
Cappelli
B
,
Volt
F
,
Tozatto-Maio
K
, et al
.
Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease [published online ahead of print 24 April 2019]
.
Haematologica
.
2019
;
haematol.2019.216788
.
39.
Angelucci
E
,
Matthes-Martin
S
,
Baronciani
D
, et al;
EBMT Inborn Error and EBMT Paediatric Working Parties
.
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
.
Haematologica
.
2014
;
99
(
5
):
811
-
820
.
40.
Ware
RE
,
Rees
RC
,
Sarnaik
SA
, et al;
BABY HUG Investigators
.
Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial
.
J Pediatr
.
2010
;
156
(
1
):
66
-
70.e1
.
41.
Rogers
ZR
,
Wang
WC
,
Luo
Z
, et al;
BABY HUG
.
Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial
.
Blood
.
2011
;
117
(
9
):
2614
-
2617
.
42.
Kwiatkowski
JL
,
Zimmerman
RA
,
Pollock
AN
, et al
.
Silent infarcts in young children with sickle cell disease
.
Br J Haematol
.
2009
;
146
(
3
):
300
-
305
.
43.
Schatz
J
,
Brown
RT
,
Pascual
JM
,
Hsu
L
,
DeBaun
MR
.
Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease
.
Neurology
.
2001
;
56
(
8
):
1109
-
1111
.
44.
Watkins
BK
,
Horan
J
,
Storer
B
,
Martin
PJ
,
Carpenter
PA
,
Flowers
ME
.
Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant
.
Bone Marrow Transplant
.
2017
;
52
(
4
):
625
-
626
.
45.
Flowers
ME
,
Inamoto
Y
,
Carpenter
PA
, et al
.
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria
.
Blood
.
2011
;
117
(
11
):
3214
-
3219
.
46.
Atay
D
,
Erbey
F
,
Akcay
A
,
Ozturk
G
.
Is ABO mismatch another risk factor for allogeneic hematopoietic stem cell transplantation in pediatric thalassemic patients?
Pediatr Transplant
.
2015
;
19
(
6
):
645
-
651
.
47.
Logan
AC
,
Wang
Z
,
Alimoghaddam
K
, et al
.
ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation
.
Biol Blood Marrow Transplant
.
2015
;
21
:
746
-
754
.
48.
Hirokawa
M
,
Fukuda
T
,
Ohashi
K
, et al
.
Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors
.
Biol Blood Marrow Transplant
.
2013
;
19
:
1026
-
1032
.
49.
Khemani
K
,
Ross
D
,
Sinha
C
,
Haight
A
,
Bakshi
N
,
Krishnamurti
L
.
Experiences and decision making in hematopoietic stem cell transplant in sickle cell disease: patients’ and caregivers’ perspectives
.
Biol Blood Marrow Transplant
.
2018
;
24
:
1041
-
1048
.
50.
Bakshi
N
,
Sinha
CB
,
Ross
D
,
Khemani
K
,
Loewenstein
G
,
Krishnamurti
L
;
Proponent or collaborative
.
Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease
.
PLoS One
.
2017
;
12
(
7
):
e0178413
.
51.
Meier
ER
,
Dioguardi
JV
,
Kamani
N
.
Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia
.
Pediatr Blood Cancer
.
2015
;
62
(
7
):
1277
-
1284
.
52.
Nickel
RS
,
Kamani
NR
.
Ethical challenges in hematopoietic cell transplantation for sickle cell disease
.
Biol Blood Marrow Transplant
.
2018
;
24
:
219
-
227
.
53.
Nickel
RS
,
Hendrickson
JE
,
Haight
AE
.
The ethics of a proposed study of hematopoietic stem cell transplant for children with “less severe” sickle cell disease
.
Blood
.
2014
;
124
(
6
):
861
-
866
.
54.
Thompson
AL
,
Bridley
A
,
Twohy
E
, et al
.
An educational symposium for patients with sickle cell disease and their families: results from surveys of knowledge and factors influencing decisions about hematopoietic stem cell transplant
.
Pediatr Blood Cancer
.
2013
;
60
(
12
):
1946
-
1951
.
55.
Ciurea
SO
,
Cao
K
,
Fernandez-Vina
M
, et al
.
The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation [published correction appears in Bone Marrow Transplant. 2019;54(5):784]
.
Bone Marrow Transplant
.
2018
;
53
(
5
):
521
-
534
.
56.
Aguilar-Salinas
P
,
Hayward
K
,
Santos
R
, et al
.
Surgical revascularization for pediatric patients with sickle cell disease and moyamoya disease in the prevention of ischemic strokes: a single-center case series and a systematic review
.
World Neurosurg
.
2019
;
123
:
435
-
442.e8
.
57.
Yeruva
SL
,
Paul
Y
,
Oneal
P
,
Nouraie
M
.
Renal failure in sickle cell disease: prevalence, predictors of disease, mortality and effect on length of hospital stay
.
Hemoglobin
.
2016
;
40
(
5
):
295
-
299
.
58.
Drawz
P
,
Ayyappan
S
,
Nouraie
M
, et al
.
Kidney disease among patients with sickle cell disease, hemoglobin SS and SC
.
Clin J Am Soc Nephrol
.
2016
;
11
(
2
):
207
-
215
.
59.
Allen
ES
,
Srivastava
K
,
Hsieh
MM
, et al
.
Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study
.
Lancet Haematol
.
2017
;
4
(
11
):
e553
-
e561
.
60.
Wiebking
V
,
Hütker
S
,
Schmid
I
,
Immler
S
,
Feuchtinger
T
,
Albert
MH
.
Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease
.
Ann Hematol
.
2017
;
96
(
8
):
1373
-
1377
.
61.
Gyurkocza
B
,
Sandmaier
BM
.
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
.
Blood
.
2014
;
124
(
3
):
344
-
353
.
62.
Bacigalupo
A
,
Ballen
K
,
Rizzo
D
, et al
.
Defining the intensity of conditioning regimens: working definitions
.
Biol Blood Marrow Transplant
.
2009
;
15
:
1628
-
1633
.
63.
Horan
JT
,
Haight
A
,
Dioguardi
JL
, et al
.
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial
.
Biol Blood Marrow Transplant
.
2015
;
21
:
900
-
905
.
64.
Strocchio
L
,
Zecca
M
,
Comoli
P
, et al
.
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease
.
Br J Haematol
.
2015
;
169
(
5
):
726
-
736
.
65.
Iannone
R
,
Casella
JF
,
Fuchs
EJ
, et al
.
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia
.
Biol Blood Marrow Transplant
.
2003
;
9
:
519
-
528
.
66.
Horan
JT
,
Liesveld
JL
,
Fenton
P
,
Blumberg
N
,
Walters
MC
.
Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin
.
Bone Marrow Transplant
.
2005
;
35
(
2
):
171
-
177
.
67.
Guilcher
GMT
,
Monagel
DA
,
Nettel-Aguirre
A
, et al
.
Nonmyeloablative matched sibling donor hematopoietic cell transplantation in children and adolescents with sickle cell disease
.
Biol Blood Marrow Transplant
.
2019
;
25
(
6
):
1179
-
1186
.
68.
Maheshwari
S
,
Kassim
A
,
Yeh
RF
, et al
.
Targeted busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant
.
Bone Marrow Transplant
.
2014
;
49
(
3
):
366
-
369
.
69.
Abraham
A
,
Stenger
E
,
Travers
CD
, et al
.
Similar event-free survival but higher incidence of mixed T cell chimerism after hematopoietic cell transplantation for sickle cell disease using rabbit versus horse ATG: a Study from the Sickle Transplant Alliance for Research (STAR) [abstract]
.
Blood
.
2017
;
130
(
suppl 1
). Abstract
3535
.
70.
Gilman
AL
,
Eckrich
MJ
,
Epstein
S
, et al
.
Alternative donor hematopoietic stem cell transplantation for sickle cell disease
.
Blood Adv
.
2017
;
1
(
16
):
1215
-
1223
.
71.
Foell
J
,
Pfirstinger
B
,
Rehe
K
,
Wolff
D
,
Holler
E
,
Corbacioglu
S
.
Haploidentical stem cell transplantation with CD3+-/CD19+-depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study
.
Bone Marrow Transplant
.
2017
;
52
(
6
):
938
-
940
.
72.
Gaziev
J
,
Isgrò
A
,
Sodani
P
, et al
.
Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRαβ+/CD19+-depleted grafts
.
Blood Adv
.
2018
;
2
(
3
):
263
-
270
.
73.
Olsson
R
,
Remberger
M
,
Schaffer
M
, et al
.
Graft failure in the modern era of allogeneic hematopoietic SCT [published correction appears in Bone Marrow Transplant. 2013;48(4):616]
.
Bone Marrow Transplant
.
2013
;
48
(
4
):
537
-
543
.
74.
Horan
J
,
Wang
T
,
Haagenson
M
, et al
.
Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders
.
Blood
.
2012
;
120
(
14
):
2918
-
2924
.
75.
Ribeil
JA
,
Hacein-Bey-Abina
S
,
Payen
E
, et al
.
Gene therapy in a patient with sickle cell disease
.
N Engl J Med
.
2017
;
376
(
9
):
848
-
855
.
76.
Abraham
A
,
Hsieh
M
,
Eapen
M
, et al
.
Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease
.
Biol Blood Marrow Transplant
.
2017
;
23
:
2178
-
2183
.
77.
Fitzhugh
CD
,
Cordes
S
,
Taylor
T
, et al
.
At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT
.
Blood
.
2017
;
130
(
17
):
1946
-
1948
.
78.
Wu
CJ
,
Gladwin
M
,
Tisdale
J
, et al
.
Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis
.
Br J Haematol
.
2007
;
139
(
3
):
504
-
507
.
79.
Shenoy
S
,
Gaziev
J
,
Angelucci
E
, et al
.
Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT
.
Biol Blood Marrow Transplant
.
2018
;
24
:
1313
-
1321
.
80.
Walters
MC
,
Sullivan
KM
,
Bernaudin
F
, et al
.
Neurologic complications after allogeneic marrow transplantation for sickle cell anemia
.
Blood
.
1995
;
85
(
4
):
879
-
884
.
81.
Gaziev
J
,
Marziali
S
,
Paciaroni
K
, et al
.
Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies
.
Biol Blood Marrow Transplant
.
2017
;
23
:
1531
-
1540
.
82.
Solh
Z
,
Taccone
MS
,
Marin
S
,
Athale
U
,
Breakey
VR
.
Neurological PRESentations in sickle cell patients are not always stroke: a review of posterior reversible encephalopathy syndrome in sickle cell disease
.
Pediatr Blood Cancer
.
2016
;
63
(
6
):
983
-
989
.
83.
Pegelow
CH
,
Colangelo
L
,
Steinberg
M
, et al
.
Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia
.
Am J Med
.
1997
;
102
(
2
):
171
-
177
.
84.
Thompson
CB
,
June
CH
,
Sullivan
KM
,
Thomas
ED
.
Association between cyclosporin neurotoxicity and hypomagnesaemia
.
Lancet
.
1984
;
2
(
8412
):
1116
-
1120
.
85.
June
CH
,
Thompson
CB
,
Kennedy
MS
,
Loughran
TP
Jr.
,
Deeg
HJ
.
Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients
.
Transplantation
.
1986
;
41
(
1
):
47
-
51
.
86.
Darbari
DS
,
Liljencrantz
J
,
Ikechi
A
, et al
.
Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant
.
Br J Haematol
.
2019
;
184
(
4
):
690
-
693
.
87.
Gladwin
MT
,
Sachdev
V
,
Jison
ML
, et al
.
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease
.
N Engl J Med
.
2004
;
350
(
9
):
886
-
895
.
88.
Gladwin
MT
,
Barst
RJ
,
Gibbs
JS
, et al;
walk-PHaSST Investigators and Patients
.
Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom
.
PLoS One
.
2014
;
9
(
7
):
e99489
.
89.
Lerner
D
,
Dandoy
C
,
Hirsch
R
,
Laskin
B
,
Davies
SM
,
Jodele
S
.
Pericardial effusion in pediatric SCT recipients with thrombotic microangiopathy
.
Bone Marrow Transplant
.
2014
;
49
(
6
):
862
-
863
.
90.
Cox
K
,
Punn
R
,
Weiskopf
E
,
Pinsky
BA
,
Kharbanda
S
.
Pericardial effusion following hematopoietic cell transplantation in children and young adults is associated with increased risk of mortality
.
Biol Blood Marrow Transplant
.
2017
;
23
:
1165
-
1169
.
91.
Brown
AK
,
Sleeper
LA
,
Miller
ST
,
Pegelow
CH
,
Gill
FM
,
Waclawiw
MA
;
Cooperative Study of Sickle Cell Disease
.
Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease
.
Arch Pediatr Adolesc Med
.
1994
;
148
(
8
):
796
-
804
.
92.
Martin
OO
,
Moquist
KL
,
Hennessy
JM
,
Nelson
SC
.
Invasive pneumococcal disease in children with sickle cell disease in the pneumococcal conjugate vaccine era [published online ahead of print 4 July 2017]
.
Pediatr Blood Cancer
.
2018
;
65
(
1
):
e26713
.
93.
Kulkarni
S
,
Powles
R
,
Treleaven
J
, et al
.
Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants
.
Blood
.
2000
;
95
(
12
):
3683
-
3686
.
94.
Tomblyn
M
,
Chiller
T
,
Einsele
H
, et al
.
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective
.
Biol Blood Marrow Transplant
.
2009
;
15
:
1143
-
1238
.
95.
Stenger
E
,
Abraham
A
,
Travers
CD
, et al
.
Development of a multi-center cohort to evaluate long-term outcomes and late effects following hematopoietic cell transplantation for sickle cell disease: a STAR Initiative [abstract]
.
Blood
.
2017
;
130
(
suppl 1
). Abstract
3271
.
96.
Shenoy
S
,
Angelucci
E
,
Arnold
SD
, et al
.
Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation
.
Biol Blood Marrow Transplant
.
2017
;
23
:
552
-
561
.
97.
Brendel
C
,
Guda
S
,
Renella
R
, et al
.
Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype
.
J Clin Invest
.
2016
;
126
(
10
):
3868
-
3878
.
98.
Urbinati
F
,
Wherley
J
,
Geiger
S
, et al
.
Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease
.
Cytotherapy
.
2017
;
19
(
9
):
1096
-
1112
.
99.
Arnold
SD
,
Brazauskas
R
,
He
N
, et al
.
Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases
.
Haematologica
.
2017
;
102
(
11
):
1823
-
1832
.
You do not currently have access to this content.